Shares in Swiss biotech Actelion (
Bloomberg said the New Brunswick, N.J. company has approached the Swiss business with an offer worth about $17 billion.
People familiar with the situation told Bloomberg Actelion is working with an adviser to explore its options. Actelion couldn't immediately be reached for comment.
Actelion is led by fiercely independent co-founder...